Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2003
05/22/2003WO2002044144A3 Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
05/22/2003WO2002030924A9 Quinazoline derivatives with anti-tumour activity
05/22/2003WO2002024146A3 Methods of decreasing or preventing pain using spicamycin derivatives
05/22/2003WO2001074298A3 Methods and compositions for regulating memory consolidation
05/22/2003WO2001070941A9 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
05/22/2003WO2001015736A3 Interferon-beta conjugates
05/22/2003US20030097671 Inhibition of betaarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
05/22/2003US20030097667 For therapy of Alzheimers disease, diagnosis
05/22/2003US20030097023 For prophylaxis and therapy of immunological diseases, asthma, abnormal bone formation, neuronal cell death, lung failure, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardiac ischemia
05/22/2003US20030097004 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists
05/22/2003US20030097000 2-Phenyl-quinoline derivatives, preparation method and therapeutic use thereof
05/22/2003US20030096973 Recombinant collagens and derived proteins produced by plants, methods of obtaining such and their uses
05/22/2003US20030096873 Administering therapeutically effective amount of (+)-bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (-)-stereoisomer for therapy of pain
05/22/2003US20030096865 Composition for improving sleep quality and efficiency , and methods of preparing and using the composition
05/22/2003US20030096859 Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
05/22/2003US20030096858 The parent drug compound is modified by forming one or more of predetermined chemical arrangement within parent drug structure for programming specific course and rate of metabolism for drug that leads to inactive nontoxic metabolite
05/22/2003US20030096852 Inhibiting binding interaction between hGH (human growth hormone) or a mutant thereof and an hGH binding protein or receptor in mammal administering benzimidazole compound
05/22/2003US20030096844 Cannabinoid receptor ligands
05/22/2003US20030096840 Granule formulation
05/22/2003US20030096838 Novel triazolo-pyridines anti-inflammatory compounds
05/22/2003US20030096833 Use in inhibiting inflammation, cell death and in treating shock and reperfusion injuries
05/22/2003US20030096832 Method of treating pain using nalbuphine and opioid antagonists
05/22/2003US20030096829 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
05/22/2003US20030096827 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition
05/22/2003US20030096826 Inhibitors of interleukin-1 beta converting enzyme and other cysteine proteases in the ICE family
05/22/2003US20030096819 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
05/22/2003US20030096817 Inhibiting mammalian protein kinases (p38) with (2,6-difluoro-phenyl)-(5-iodo-pyridin-2-yl)amine for treatment of cardiovascular disorders
05/22/2003US20030096816 Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents
05/22/2003US20030096811 Such as cis-(4-dimethylaminomethyl-3-hydroxy-3-(3-methoxy-phenyl)-cyclohexanone for treatment of pain, inflammation, allergies, depression, drug/alcohol abuse, gastritis, itching, cardiovascular/repiratory diseases, epilepsy, and diarrhea
05/22/2003US20030096805 Antidepressants and their analogues as long-acting local anesthetics and analgesics
05/22/2003US20030096802 Pentanoic acid derivatives
05/22/2003US20030096796 N-cyanomethyl amides which are cysteine protease inhibitors; use treating diseases associated with activity of cathepsins B, K, L or S such as autoimmune disorders, allergic disorder, allogeneic immune response, cardiovascular disorders
05/22/2003US20030096794 Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof
05/22/2003US20030096792 Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
05/22/2003US20030096788 Adenosine derivatives
05/22/2003US20030096746 Compounds and methods for inhibiting cancer metastasis
05/22/2003US20030096739 Nuclear receptor-mediated introduction of a PNA into cell nuclei
05/22/2003US20030096737 Caspase inhibitors and uses thereof
05/22/2003US20030096299 Natural ligand of G protein coupled receptor ChemR23 and uses thereof
05/22/2003US20030096297 Method for identifying inhibitors of G protein coupled receptor signaling
05/22/2003US20030096012 Film-forming powder, compositions containing it, methods for their preparation and their uses
05/22/2003US20030096000 Encapsulation of nanosuspensions in liposomes and microspheres
05/22/2003US20030095992 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots
05/22/2003US20030095960 Three human transferases, polynucleotides that identify and encode them, expression vectors, host cells, antibodies, agonists, and antagonists.
05/22/2003US20030095958 Inhibiting beta amyloid converting enzyme responsible for A beta peptide cleavage to treat Alzheimer's Disease, Down's Syndrome, etc.
05/22/2003CA2756866A1 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003CA2472019A1 Production of cell suspensions
05/22/2003CA2468171A1 Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
05/22/2003CA2467347A1 Histamine receptor h3 polynucleotides
05/22/2003CA2467267A1 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase
05/22/2003CA2467258A1 Agent for inducing embryonic stem cell to ectodermal cell, method for obtaining the same and use of the same.
05/22/2003CA2467081A1 Pyrazole derivatives as psychopharmaceuticals
05/22/2003CA2466962A1 Aryl aniline beta-2 adrenergic receptor agonists
05/22/2003CA2466632A1 Injectable depot compositions and uses thereof
05/22/2003CA2466519A1 Method for treating autoimmune diseases
05/22/2003CA2466465A1 Nk1 antagonists
05/22/2003CA2466440A1 Cannabinoid receptor ligands
05/22/2003CA2466415A1 Pgc-1.beta., a novel pgc-1 homologue and uses therefor
05/22/2003CA2466355A1 Neurotransmitter balance chemotherapy
05/22/2003CA2466344A1 Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
05/22/2003CA2466264A1 Three-dimensional structure of prostaglandin d synthase and utilization thereof
05/22/2003CA2466115A1 Cyanoalkylamino derivatives as protease inhibitors
05/22/2003CA2466055A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
05/22/2003CA2465868A1 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003CA2465861A1 Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
05/22/2003CA2464863A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003CA2464861A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003CA2464419A1 Benzimidazoles useful as protein kinase inhibitors
05/22/2003CA2464347A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003CA2463970A1 Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain
05/22/2003CA2460959A1 Enzymes
05/21/2003EP1312601A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
05/21/2003EP1312367A1 Heterocyclo-alkylsulfonyl pyrazolesa and their use as COX-2 inhibitors
05/21/2003EP1312363A1 Methods of treatment and kits comprising a growth hormone secretagogue
05/21/2003EP1312362A1 Method for the suppression of visceral pain by regulating T-type calcium channel
05/21/2003EP1312356A1 Aqueous suspension preparations
05/21/2003EP1311684A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them
05/21/2003EP1311677A2 Regulation of human p2y1-like g protein-coupled receptor
05/21/2003EP1311667A2 Transgenic animal model for neurodegerative disease and uses thereof
05/21/2003EP1311664A2 Microtubule-associated proteins and tubulins
05/21/2003EP1311543A1 T cell receptor v beta-d beta-j beta sequence and methods for its detection
05/21/2003EP1311534A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds
05/21/2003EP1311533A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase
05/21/2003EP1311532A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
05/21/2003EP1311525A2 Composition and method for inhibiting platelet aggregation
05/21/2003EP1311511A1 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity
05/21/2003EP1311510A1 2,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonvulsive action and methods for producing the same
05/21/2003EP1311508A2 Novel beta-amyloid inhibitors, method for producing the same and the use thereof as medicaments
05/21/2003EP1311507A1 Fused pyrazole derivatives being protein kinase inhibitors
05/21/2003EP1311505A2 Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
05/21/2003EP1311503A1 Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1 receptors and/or dopamine d2 receptors
05/21/2003EP1311499A2 Bicyclic compounds as h3 receptor ligands
05/21/2003EP1311488A1 Substituted imidazoles as tafia inhibitors
05/21/2003EP1311482A2 Non-imidazole aryloxypiperidines as h3 receptor ligands
05/21/2003EP1311478A1 Novel thiourea compounds and the pharmaceutical compositions containing the same
05/21/2003EP1311474A1 Sulfonamide derivatives
05/21/2003EP1311471A1 Phenyl- and phenylalkyl-substituted ethanolamines and ethylenediamines
05/21/2003EP1311298A2 System for regulating in vivo the expression of a transgene by conditional inhibition
05/21/2003EP1311297A1 A method for reducing stress-induced overproduction of neuropeptide y in an individual
05/21/2003EP1311293A2 Combinations of ssri and estrogenic agents
1 ... 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 ... 1833